three years of small molecule threads, summarised so you do not have to read them
three years of small molecule threads, summarised so you do not have to read them. Change my mind, genuinely — I have no stake in being right about this. Analytically this is a small-molecule identity and purity problem, not a peptide one. The methods, the impurity classes and the reference standards are all…
Because it is not a peptide, it is not subject to the same degradation pathways, does not require the absorption enhancers used for oral peptides, and can be formulated as a conventional tablet.
Phase 2 or phase 3?
the boards keep comparing it to injectables at matched doses, which is meaningless
Corrected a cross-class dose comparison in the title. The body is untouched.
oral semaglutide is a peptide with an absorption enhancer, this is not that
Compared milligram figures across two completely different molecule classes in a comment. Deserved the correction.
small molecule, not a peptide, and that changes everything about it
Correction: that is the oral peptide product, which is a different thing entirely. This one is a small molecule.
Read both programme names carefully after mixing them up in a comment and being politely corrected.
Has anyone here seen independent identity testing on this?